Lasinavir
Alternative Names: BMS 234475; CGP 61755Latest Information Update: 09 Oct 2002
At a glance
- Originator Novartis
- Developer Bristol-Myers Squibb
- Class Antivirals
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 09 Oct 2002 Discontinued - Phase-I for HIV infections treatment in USA (PO)
- 12 Feb 1999 BMS 234475 is now called lasinavir
- 17 Jul 1997 Phase-I clinical trials for HIV infections treatment in USA (PO)